Niche Market Moves: Major Overhauls From Energy to AI InfrastructureGlobal Report·Jul 22 at 04:17 AMWLLBW0.00%BMEA0.00%
Unbundling the Long Tail: Narrative Arbitrage and Value Chain RealitiesGlobal Report·Jul 9 at 05:03 AMNTRB0.00%KYCCF0.00%
Markets Weigh Cross-Sector Fundamentals for Signals on the Next Economic PhaseGlobal Report·Jul 8 at 10:32 PMNEXA0.00%PCRHY0.00%
Biomea Presents Promising Phase 2 Data For Icovamenib In Diabetes; Advances Phase 1 For BMF-650nasdaq·Jun 8 at 07:10 AMBMEA0.00%
Biomea Fusion Presents New Clinical and Translational Data for Icovamenib at the American Diabetes Association (“ADA”) 86th Scientific Sessions and Announces Expansion of Ongoing Phase I BMF-650 Study | BMEA Stock NewsStockTitan·Jun 5 at 10:35 AMBMEA0.00%
Biomea Fusion Reports First Quarter 2026 Financial Results and Corporate Highlights | BMEA Stock NewsStockTitan·May 11 at 07:55 AMBMEA0.00%
Biomea Fusion Announces Poster Presentations of Icovamenib at the American Diabetes Association (ADA) 86th Scientific Sessions | BMEA Stock NewsStockTitan·May 5 at 08:50 AMBMEA0.00%FBT0.00%
Biomea Fusion Status Update: Experts Discuss Icovamenib’s Promise Ahead of ADA 2026Market Beat·May 5 at 03:20 PMBMEA0.00%IBB0.00%
